DGAP-News: Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board
06.02.2019 (www.4investors.de) -
DGAP-News: Resinco Capital Partners Inc. / Key word(s): Miscellaneous
Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board
06.02.2019 / 06:01
The issuer is solely responsible for the content of this announcement.
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2019) - Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the 'Company' or 'Resinco') is pleased to announce that the Company has appointed pioneer and trailblazer of modern immunology, Sir Marc Feldmann, to its Advisory Board after fully acquiring his company, ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair.Sir Marc Feldmann, whose research breakthrough on inflammation led to the creation of some of the world's top-selling drugs like Humira and Remicade, is embracing medical marijuana, through co-founding ReFormation Pharmaceuticals with Professor Jagdeep Nanchahal. Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. 'As medical marijuana regulations ease, Feldmann is paving the way for a new class of cannabis derived-drugs to treat pain and other conditions. His background and expertise will be valuable as we accelerate growth in the medical marijuana pharmaceutical space and capitalize on the industry's evolution,' says Alex Somjen, President & CEO of Resinco. 'I am pleased to chair Resinco's Advisory Board and work with the team to advance the Second Generation of the Medical cannabis industry,' said Sir Marc Feldmann, Chairman and Founder of ReFormation Pharmaceuticals. 'Through rigorous clinical trials using FDA approved practices, we intend to accelerate ReFormation's development of cannabis treatments triggering stem cell repair, where the medical benefits are based on hard science and government regulation.' About Resinco Capital PartnersResinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile. Website: www.resincocp.comAbout ReFormation Pharmaceuticals CorpReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company's research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford. Website: https://www.reformationpharma.com/ Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Information: This news release includes certain statements that may be deemed 'forward-looking statements'. The use of any of the words 'anticipate', 'continue', 'estimate', 'expect', 'may', 'will', 'would', 'project', 'should', 'believe' and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com.RESINCO CAPITAL PARTNERS INC.:Company ContactMr. Alexander Somjen, CEO647-362-8998Media ContactTim Gray, Account Director KCSA Strategic CommunicationsPhone: 212.682.6300Email: Resinco@KCSA.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/42665
Click on, or paste the following link into your web browser, to view
the associated documents
06.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Resinco Capital Partners Inc.
End of News
DGAP News Service